Anzeige
Meldung des Tages: Revolutionäre Entwicklung im Megatrend – Der KI-Durchbruch für Pflege und Sicherheit!

Charlottes Web Aktie News

Aktie
WKN:  A2N434 ISIN:  CA16106R1091 US-Symbol:  CWBHF Branche:  Pharmazeutika Land:  USA
0,499025 $
-0,001 $
-0,20%
0,42286 € 15:36:54 Uhr
Depot/Watchlist
Marktkapitalisierung *
50,84 Mio. €
Streubesitz
96,24%
KGV
-0,47
Index-Zuordnung
-

Charlottes Web News

23.01.26 - PR Newswire
Charlotte's Web Commends Representative Griffith for Leadership Introducing Hemp Enforcement, Modernization, and Protection (HEMP) Act
Charlotte's Web Commends Representative Griffith for Leadership Introducing Hemp Enforcement, Modernization, and Protection (HEMP) Act PR Newswire
19.12.25 - PR Newswire
Presidential Executive Order Validates DeFloria's Strategy in Pharmaceutical Cannabinoid Drug Development
Presidential Executive Order Validates DeFloria's Strategy in Pharmaceutical Cannabinoid Drug Development PR Newswire
18.12.25 - PR Newswire
Charlotte's Web Serves as a Premier CBD Partner for Landmark Medicare and Medicaid Pilot Program
Charlotte's Web Serves as a Premier CBD Partner for Landmark Medicare and Medicaid Pilot Program PR Newswire
12.11.25 - PR Newswire
Charlotte's Web Reports Q3 2025 Results
Charlotte's Web Reports Q3 2025 Results PR Newswire
21.10.25 - PR Newswire
Charlotte's Web Appoints M. Borgia Walker to Board of Directors
Charlotte's Web Appoints M. Borgia Walker to Board of Directors PR Newswire
14.10.25 - PR Newswire
Charlotte's Web™ Expands its Brightside Line with Launch of Knockout Hemp THC Sleep Gummies
Charlotte's Web™ Expands its Brightside Line with Launch of Knockout Hemp THC Sleep Gummies PR Newswire
30.09.25 - PR Newswire
Charlotte's Web™ Expands Sleep Category with Launch of Quiet Sleep Mushroom Gummies
Charlotte's Web™ Expands Sleep Category with Launch of Quiet Sleep Mushroom Gummies PR Newswire
04.09.25 - PR Newswire
Charlotte's Web Announces Plans to Establish a Scientific Advisory Board
Charlotte's Web Announces Plans to Establish a Scientific Advisory Board PR Newswire
13.08.25 - PR Newswire
Charlotte's Web Reports Year-Over-Year Growth For Q2 2025
Charlotte's Web Reports Year-​Over-Year Growth For Q2 2025 PR Newswire
05.08.25 - PR Newswire
Charlotte's Web 2025 Second Quarter Earnings Call and Webcast Notice
Charlotte's Web 2025 Second Quarter Earnings Call and Webcast Notice PR Newswire
13.06.25 - PR Newswire
Charlotte's Web Reports Shareholder Meeting Voting Results
Charlotte's Web Reports Shareholder Meeting Voting Results PR Newswire
27.05.25 - PR Newswire
Charlotte's Web™ Unveiling Brightside™ Precision-Formulated Approach to Hemp-Derived THC at Benzinga Conference
Charlotte's Web™ Unveiling Brightside™ Precision-​Formulated Approach to Hemp-​Derived THC at Benzinga Conference PR Newswire
14.05.25 - PR Newswire
Charlotte's Web Reports Year-Over-Year Growth For Q1 2025
Charlotte's Web Reports Year-​Over-Year Growth For Q1 2025 PR Newswire
19.03.25 - PR Newswire
Charlotte's Web Reports 2024 Fourth Quarter and Year-End Financial Results
Charlotte's Web Reports 2024 Fourth Quarter and Year-End Financial Results PR Newswire
25.02.25 - PR Newswire
Charlotte's Web 2024 Fourth Quarter Earnings Call and Webcast Notice
Charlotte's Web 2024 Fourth Quarter Earnings Call and Webcast Notice PR Newswire
24.02.25 - PR Newswire
Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment
Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment PR Newswire
24.02.25 - PR Newswire
DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)
DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of ...

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »